Wednesday, November 18, 2026

SK chemicals' Dementia Patch Selected as a World-Class Product... 12% Global Market Share

Input
2026-11-18 10:11:04
Updated
2026-11-18 10:11:04
At the '2026 World-Class Product Certificate Presentation Ceremony' held on the 17th at LOTTE HOTEL WORLD in Jamsil, Seoul, Kim Jae-eun, director general for mid-sized enterprise policy at the Ministry of Trade, Industry and Energy (left), and Mun Jeong-hyeon, head of development at SK chemicals, pose for a commemorative photo. Courtesy of SK chemicals
[Financial News] SK chemicals' patch for treating dementia has been recognized for its competitiveness in the global market.
SK chemicals said on the 18th that its self-developed rivastigmine patch had been selected as a Current World-Class Product among the '2026 World-Class Products' overseen by the Ministry of Trade, Industry and Energy and KOTRA. It is the only pharmaceutical product among the 27 products selected this year.
The World-Class Product program selects products with global competitiveness based on factors such as global market share and export performance. Products with the potential to achieve competitiveness within the next seven years are classified as next-generation World-Class Products.
According to 2025 IQVIA data, SK chemicals' rivastigmine patch recorded annual global sales of approximately $38.3 million (about 54.5 billion won). It ranked fourth worldwide, with a 12% market share. Its declared export value that year was approximately $14.35 million (about 20.4 billion won), the highest among domestic manufacturers of similar products.
The rivastigmine patch is a treatment for Alzheimer's-type dementia that delivers medication through an application to the skin once a day. Rivastigmine, its active ingredient, inhibits the breakdown of acetylcholine, a neurotransmitter involved in cognitive functions such as memory and learning. The patch is designed to make medication easier for dementia patients who have difficulty swallowing pills or managing their medication.
SK chemicals' transdermal drug delivery system (TDS) technology was used to develop the product. Building on formulation expertise gained while developing the arthritis treatment patch Trast in the 1990s, the company began work on the rivastigmine patch in 2007. After about five years of formulation development and equivalence testing against existing medicines, it brought the product to market and received approval for Europe's first generic rivastigmine patch.
The company later expanded sales beyond Europe to regions including Latin America and the Middle East, and obtained marketing approval from the U.S. Food and Drug Administration (FDA) in 2019.
SK chemicals plans to continue developing medicines that make it easier for patients to take their medication, drawing on its formulation technology.

[email protected] Jung Sang-hee Reporter